Purification of Leukemia-Derived Exosomes to Study Microenvironment Modulation

Pierson, Sandrine; Gargiulo, Ernesto; Guerin, Coralie L.; Moussay, Etienne; Paggetti, Jérôme

doi:10.1007/978-1-4939-8885-3_16

Cited by 10 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to cellular communication, exosomes are known to be associated with immune reactions, cancer viability and invasion, antigen presentation, and cell migration and differentiation (53). Recently, a number of studies have demonstrated the role of these EVs in hematological malignancies (21)(22)(23), as well as their involvement at different diseases phases (33,53).…”

Section: Discussionmentioning

confidence: 99%

“…currently, at least to the best of our knowledge, there are no studies available reporting the possibility of enriching the tumor-derived exosome fraction in patients affected by different types of leukemia. However, certain groups have revealed that exosomes isolated from cell line cultures modulate the crosstalk between leukemia cells and the bone marrow (BM) microenvironment, and that they also carry molecular tumor markers (21)(22)(23)(24). Moreover, recent studies have indicated that leukemia-derived exosomes can be utilized as prognostic (25), diagnostic (26) and therapeutic biomarkers (27) for individuals suffering from different hematologic malignancies, such as acute myeloid leukemia (28)(29)(30), multiple myeloma (31) and chronic lymphocytic leukemia (32).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia

et al. 2019

View full text Add to dashboard Cite

due to the discovery of their role in intra-cellular communications, exosomes, which carry information specific to the cell of origin, have garnered considerable attention in cancer research. Moreover, there is evidence to suggest the possibility of isolating different exosome sub-populations based on target antigens at the cell surface. Philadelphia chromosome-positive (Ph +) chronic myeloid leukemia (cML) is a clonal myeloproliferative neoplasia characterized by the breakpoint cluster region-proto-oncogene 1 tyrosine-protein kinase (BcR-ABL1) fusion-gene, derived from the t (9;22) translocation. Tyrosine kinase inhibitors (TKIs) target BcR-ABL1 protein and induce major or deep molecular responses in the majority of patients. despite the fact that several studies have demonstrated the persistence of leukemic cells in the bone marrow niche, even following treatment, TKIs prolong patient survival time and facilitate treatment-free remission. These characteristics render cML a plausible model for investigating the feasibility of tumor-derived exosome fraction enrichment. In the present study, patients in the chronic phase (cP) of CML were treated with TKIs, and the quantification of the BCR-ABL1 exosomal transcript was performed using digital PcR (dPcR). The possibility of tumor-derived exosomes enrichment was confirmed, and for the first time, to the best of our knowledge, the detection of the BcR-ABL1 transcript highlighted the presence of active leukemic cells in patients with CP-CML. According to these findings, tumor-derived exosomes may be considered a novel tool for the identification of active leukemic cells, and for the assessment of innovative monitoring focused on the biological functions of exosomes in cML.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…EVs, in particular exosomes, lately attracted a considerable interest in cancer research [2] and several data are suggesting that they play an important role also in the onco-hematologic field [3]: first, because they carry out important disease markers for leukemogenesis understanding [4,5], second because of their diagnostic potential [6], and last, but not least, for the monitoring of the minimal residual disease [7].…”

Section: Dear Editormentioning

confidence: 99%

dsDNA from extracellular vesicles (EVs) in adult AML

et al. 2020

View full text Add to dashboard Cite

“…Indeed, due to their small size, heterogeneity, the presence of contaminants (e.g., soluble proteins) and isolation methods used, small EV detection and correct classification can be challenging, and thus, caution must be applied. Consequently, it is important to consider these issues when making definitive conclusion about small EV cargo, function and characterization [1,79].…”

Section: Generality On Small Evs and The Tumor Microenvironmentmentioning

confidence: 99%

Hematological Malignancy-Derived Small Extracellular Vesicles and Tumor Microenvironment: The Art of Turning Foes into Friends

Gargiulo

Paggetti

Moussay

2019

Cells

Self Cite

View full text Add to dashboard Cite

Small extracellular vesicles (small EVs) are commonly released by all cells, and are found in all body fluids. They are implicated in cell to cell short- and long-distance communication through the transfer of genetic material and proteins, as well as interactions between target cell membrane receptors and ligands anchored on small EV membrane. Beyond their canonical functions in healthy tissues, small EVs are strategically used by tumors to communicate with the cellular microenvironment and to establish a proper niche which would ultimately allow cancer cell proliferation, escape from the immune surveillance, and metastasis formation. In this review, we highlight the effects of hematological malignancy-derived small EVs on immune and stromal cells in the tumor microenvironment.

show abstract

Purification of Leukemia-Derived Exosomes to Study Microenvironment Modulation

Cited by 10 publications

References 13 publications

Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia

Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia

dsDNA from extracellular vesicles (EVs) in adult AML

Hematological Malignancy-Derived Small Extracellular Vesicles and Tumor Microenvironment: The Art of Turning Foes into Friends

Contact Info

Product

Resources

About